Keros Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $36.375
- Today's High:
- $37.47
- Open Price:
- $36.56
- 52W Low:
- $33.09
- 52W High:
- $59.96
- Prev. Close:
- $36.51
- Volume:
- 197890
Company Statistics
- Market Cap.:
- $1.07 billion
- Book Value:
- 11
- Revenue TTM:
- $20 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-87265000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.05%
- Return on Equity TTM:
- -47.09%
Company Profile
Keros Therapeutics Inc had its IPO on 2020-04-08 under the ticker symbol KROS.
The company operates in the Healthcare sector and Biotechnology industry. Keros Therapeutics Inc has a staff strength of 121 employees.
Stock update
Shares of Keros Therapeutics Inc opened at $36.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $36.38 - $37.47, and closed at $36.6.
This is a +0.25% increase from the previous day's closing price.
A total volume of 197,890 shares were traded at the close of the day’s session.
In the last one week, shares of Keros Therapeutics Inc have increased by +0.99%.
Keros Therapeutics Inc's Key Ratios
Keros Therapeutics Inc has a market cap of $1.07 billion, indicating a price to book ratio of 5.7412 and a price to sales ratio of 68.4176.
In the last 12-months Keros Therapeutics Inc’s revenue was $20 million with a gross profit of $-87265000 and an EBITDA of $-139531008. The EBITDA ratio measures Keros Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Keros Therapeutics Inc’s operating margin was 0% while its return on assets stood at -30.05% with a return of equity of -47.09%.
In Q2, Keros Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Keros Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.69 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Keros Therapeutics Inc’s profitability.
Keros Therapeutics Inc stock is trading at a EV to sales ratio of 57.2401 and a EV to EBITDA ratio of -14.4456. Its price to sales ratio in the trailing 12-months stood at 68.4176.
Keros Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $356.31 million
- Total Liabilities
- $16.10 million
- Operating Cash Flow
- $-311000.00
- Capital Expenditure
- $311000
- Dividend Payout Ratio
- 0%
Keros Therapeutics Inc ended 2024 with $356.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $356.31 million while shareholder equity stood at $326.26 million.
Keros Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $16.10 million in other current liabilities, 3000.00 in common stock, $-301743000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $322.03 million and cash and short-term investments were $322.03 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Keros Therapeutics Inc’s total current assets stands at $334.31 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $964000.00 compared to accounts payable of $4.15 million and inventory worth $10.94 million.
In 2024, Keros Therapeutics Inc's operating cash flow was $-311000.00 while its capital expenditure stood at $311000.
Comparatively, Keros Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $36.6
- 52-Week High
- $59.96
- 52-Week Low
- $33.09
- Analyst Target Price
- $95
Keros Therapeutics Inc stock is currently trading at $36.6 per share. It touched a 52-week high of $59.96 and a 52-week low of $59.96. Analysts tracking the stock have a 12-month average target price of $95.
Its 50-day moving average was $38.3 and 200-day moving average was $45.16 The short ratio stood at 6.65 indicating a short percent outstanding of 0%.
Around 775.6% of the company’s stock are held by insiders while 9374.4% are held by institutions.
Frequently Asked Questions About Keros Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company’s lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.